Your browser doesn't support javascript.
loading
Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study.
Kato, Takeshi; Kagawa, Yoshinori; Kuboki, Yasutoshi; Gamoh, Makio; Komatsu, Yoshito; Yasui, Hirofumi; Satake, Hironaga; Oki, Eiji; Tanioka, Hiroaki; Kotaka, Masahito; Makiyama, Akitaka; Denda, Tadamichi; Goto, Masahiro; Yoshino, Takayuki; Yamazaki, Kentaro; Soeda, Junpei; Shibuya, Kazunori; Iwata, Masaru; Oba, Koji; Yamaguchi, Kensei.
Afiliação
  • Kato T; National Hospital Organization Osaka National Hospital, 2 Chome-1-14 Hoenzaka, Chuo Ward, Osaka, 540-0006, Japan.
  • Kagawa Y; Kansai Rosai Hospital, 3 Chome-1-69 Inabaso, Amagasaki, Hyogo, 660-8511, Japan.
  • Kuboki Y; National Cancer Center Hospital East, 6 Chome-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
  • Gamoh M; Osaki Citizen Hospital, Furukawa Honami, 3 Chome, Osaki, 989-6183, Japan.
  • Komatsu Y; Hokkaido University Hospital, 5 Chome Kita 14 Jonishi, Kita Ward, Sapporo, Hokkaido, 060-8648, Japan.
  • Yasui H; Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Sunto District, Shizuoka, 411-0934, Japan.
  • Satake H; Kobe City Medical Center General Hospital, 2 Chome-1-1 Minatojima Minamimachi, Chuo Ward, Kobe, Hyogo, 650-0047, Japan.
  • Oki E; Cancer Treatment Center, Kansai Medical University Hospital, 2 Chome-3-1 Shinmachi, Hirakata, Osaka, 573-1191, Japan.
  • Tanioka H; Kyushu University, Maidashi 3 Chome-1-3, Higashi Ward, Fukuoka, 812-0053, Japan.
  • Kotaka M; Okayama Rosai Hospital, 1 Chome-10-25 Chikkomidorimachi, Minami Ward, Okayama, 702-8055, Japan.
  • Makiyama A; Medical Oncology Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama, 701-0192, Japan.
  • Denda T; Sano Hospital, 2 Chome-5-1 Shimizugaoka, Tarumi Ward, Kobe, Hyogo, 655-0031, Japan.
  • Goto M; Japan Community Healthcare Organization Kyushu Hospital, 1 Chome-8-1 Kishinoura, Yahatanishi Ward, Kitakyushu, Fukuoka, 806-8501, Japan.
  • Yoshino T; Gifu University Hospital, 1-1 Yanagido, Gifu, 501-1194, Japan.
  • Yamazaki K; Chiba Cancer Center, 666-2 Nitona-cho, Chuo Ward, Chiba, 260-8717, Japan.
  • Soeda J; Osaka Medical College Hospital, 2-7 Daigakumachi, Takatsuki, Osaka, 569-0096, Japan.
  • Shibuya K; National Cancer Center Hospital East, 6 Chome-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
  • Iwata M; Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Sunto District, Shizuoka, 411-0934, Japan.
  • Oba K; Takeda Pharmaceutical Company, Ltd, Nihonbashi-Honcho 2 Chome-1-1, Chuo Ward, Tokyo, 103-8668, Japan.
  • Yamaguchi K; Takeda Pharmaceutical Company, Ltd, Nihonbashi-Honcho 2 Chome-1-1, Chuo Ward, Tokyo, 103-8668, Japan.
Int J Clin Oncol ; 26(7): 1238-1247, 2021 Jul.
Article em En | MEDLINE | ID: mdl-33928486
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Trifluridina Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Int J Clin Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Japão
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Trifluridina Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Int J Clin Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Japão